Trial Profile
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Frontotemporal dementia; Primary progressive aphasia
- Focus Pharmacodynamics
- Acronyms SLD3
- 07 Apr 2022 Planned number of patients changed from 45 to 200.
- 07 Apr 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2030.
- 07 Apr 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2030.